Results 71 to 80 of about 15,932 (195)
Equine Veterinary Journal, EarlyView.Abstract Background Treatment with the sodium‐glucose co‐transporter 2 (SGLT2) inhibitor canagliflozin in insulin dysregulated (ID) horses has shown promising results in randomised clinical trials. Larger field studies are needed to further evaluate treatment responses and potential adverse effects under real‐world conditions.
Moa Hällbom +3 more
wiley +1 more source
Dapagliflozin: A Promising Strategy to Combat Cisplatin-Induced Hepatotoxicity in Wistar Rats
BiologyRecognizing the challenges posed by chemotherapy, specifically the hepatotoxic effects of drugs like cisplatin, this study aimed to examine the hepatoprotective potential of dapagliflozin to mitigate cisplatin-induced hepatotoxicity in a rat model.
Shakta Mani Satyam +8 more
doaj +1 more source
The Kaohsiung Journal of Medical Sciences, EarlyView.ABSTRACT This study tested whether combined dapagliflozin (DAPA) and melatonin (Mel) therapy was superior to merely one for ameliorating the left ventricular (LV) fibrosis/remodeling and improving LV ejection fraction (LVEF) in rats after acute myocardial infarction (AMI). In vitro study demonstrated that DAPA treatment significantly suppressed the TGF‐
Jiunn‐Jye Sheu +6 more
wiley +1 more source
Obesity, EarlyView.Web portal for interrogating Adverse Events of GLP‐1 RA in diabetes vs weight control/obesity. ABSTRACT Objective This study aimed to assess the spectrum and frequency of adverse events (AEs) linked to glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) using the US FDA Adverse Event Reporting System (FAERS).
David Stone +3 more
wiley +1 more source
When Fat Goes Astray: Your Liver and Pancreas Get Into Trouble
Portal Hypertension &Cirrhosis, EarlyView.Metabolic dysfunction‐associated steatotic liver disease (MASLD) and intrapancreatic fat deposition (IPFD) are both common manifestations of ectopic fat accumulation. Although they share multiple risk factors, they also show notable differences in pathological features, standardization of diagnosis, and research maturity.
Yuying Chen +5 more
wiley +1 more source
Precision Medical Sciences, EarlyView.Hyperglycemia‐driven cytokine activation initiates a sustained inflammatory cascade in diabetic kidney disease, promoting cellular injury and fibrogenic signaling. Integrating cytokine‐based biomarkers with risk stratification enables precision therapeutics that target inflammation and fibrosis, ultimately aiming to halt progression from early renal ...
Emmanuel Ifeanyi Obeagu
wiley +1 more source
Smart Molecules, EarlyView.A green and simple photo‐oxygenation of benzylic C‐H bond with molecular oxygen was developed for the preparation of a series of carbonyl compounds. The straightforward C‐H carbonylation strategy features catalyst‐ and additive‐free reaction conditions, only oxygen as a green oxidant, broad scope and scalable, and the simple‐operation nature.
Jianing Li +6 more
wiley +1 more source
Acta Psychiatrica Scandinavica, EarlyView.ABSTRACT Introduction Diabetes, obesity and bipolar disorder often co‐occur and may have shared pathophysiology. Glucagon‐like peptide 1 receptor agonists (GLP‐1RA) treat diabetes and obesity but their impact on bipolar disorder is unknown. In this era of stagnated pharmacotherapy, we examined psychiatric hospitalisation and absence from work due to ...
Heidi Taipale +5 more
wiley +1 more source
Cardiorenal Outcomes of Dapagliflozin vs. Empagliflozin in Advanced Chronic Kidney Disease and Diabetes. [PDF]
Clin Pharmacol TherTarget trial emulation of a multi‐institutional electronic health record network showed comparable cardiorenal effectiveness and safety of dapagliflozin versus empagliflozin in adults with type 2 diabetes and advanced‐stage chronic kidney disease.
Lin SH +6 more
europepmc +2 more sources